PDF(Pubmed)
Abstract：
This study investigates the differential expression of miRNA gene subtypes in tumoral versus benign nevi in individuals with melanoma, aiming to identify clinically significant correlations that could serve as reliable markers for assessing tumor stage and progression. Conducted between 2019 and 2022, this descriptive, quantitative observational research analyzed 90 formalin-fixed paraffin-embedded (FFPE) samples from the Pius Brinzeu County Emergency Clinical Hospital, Timisoara, including 45 samples of advanced-stage melanoma and 45 samples of pigmented nevi. miRNA purification and analysis were performed using the miRNeasy Kit and the Human Cancer PathwayFinder miScript miRNA PCR Array, with statistical analysis (including logistic regression) to determine associations with cancer staging, such as high Breslow index risk, number of mitoses, and vascular invasion. After the analysis and comparison of 180 miRNA gene subtypes, we selected 10 of the most upregulated and 10 most downregulated genes. The results revealed that hsa-miR-133b, hsa-miR-335-5p, hsa-miR-200a-3p, and hsa-miR-885-5p were significantly upregulated in melanoma samples, with fold changes ranging from 1.09 to 1.12. Conversely, hsa-miR-451a and hsa-miR-29b-3p showed notable downregulation in melanoma, with fold changes of 0.90 and 0.92, respectively. Additionally, logistic regression analysis identified hsa-miR-29b-3p (OR = 2.51) and hsa-miR-200a-3p (OR = 2.10) as significantly associated with an increased risk of a high Breslow index, while hsa-miR-127-3p and hsa-miR-451a were associated with a reduced risk. Conclusively, this study underscores the significant alterations in miRNA expression in melanoma compared to benign nevi and highlights the potential of specific miRNAs as biomarkers for melanoma progression. The identification of miRNAs with significant associations to melanoma characteristics suggests their utility in developing non-invasive, cost-effective diagnostic tools and in guiding therapeutic decisions, potentially improving patient outcomes in melanoma management.
摘要：
这项研究调查了miRNA基因亚型在黑色素瘤个体的肿瘤和良性痣中的差异表达。旨在确定可作为评估肿瘤分期和进展的可靠标志物的临床显着相关性。在2019年至2022年之间进行，这是描述性的，定量观察研究分析了PiusBrinzeu县急诊临床医院的90份福尔马林固定石蜡包埋（FFPE）样品，蒂米什瓦拉,包括45个晚期黑色素瘤样本和45个色素痣样本。使用miRNeasy试剂盒和人类癌症PathwayFindermiScriptmiRNAPCR阵列进行miRNA纯化和分析，通过统计分析（包括逻辑回归）来确定与癌症分期的关联，例如高Breslow指数风险，有丝分裂的数量，和血管侵入。经过对180种miRNA基因亚型的分析比较,我们选择了10个上调程度最高的基因和10个下调程度最高的基因.结果显示hsa-miR-133b,hsa-miR-335-5p,hsa-miR-200a-3p,和hsa-miR-885-5p在黑色素瘤样本中显著上调，倍数变化范围从1.09到1.12。相反，hsa-miR-451a和hsa-miR-29b-3p在黑色素瘤中显示出明显的下调，倍数变化分别为0.90和0.92。此外,逻辑回归分析确定hsa-miR-29b-3p（OR=2.51）和hsa-miR-200a-3p（OR=2.10）与高Breslow指数的风险增加显着相关，而hsa-miR-127-3p和hsa-miR-451a与风险降低相关。最后，这项研究强调了与良性痣相比，黑色素瘤中miRNA表达的显著改变，并强调了特定miRNA作为黑色素瘤进展的生物标志物的潜力。与黑色素瘤特征显著相关的miRNAs的鉴定表明它们在开发非侵入性、具有成本效益的诊断工具和指导治疗决策，可能改善黑色素瘤管理中患者的预后。
